Previous 10 | Next 10 |
2024-02-09 16:23:01 ET More on Edesa Biotech Seeking Alpha’s Quant Rating on Edesa Biotech Historical earnings data for Edesa Biotech Financial information for Edesa Biotech Read the full article on Seeking Alpha For further details see: Ed...
Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...
TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management plans to participate in the 2024 Dermatology Summi...
2023-12-18 05:51:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Edesa Biotech (NASDAQ: EDSA ) just reported results for the fourth quarter of 2023. Edesa Biotech reported earnings per share of -55 cents. This was above the analyst esti...
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provid...
Industrial & Commercial Bank of China Ltd. ADR (IDCBY) is expected to report for Q3 2023 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 Bexil Corp (BXLC) is expected to report for quarter end 2023-09-30 Timberline Resources Corp. (TLRS) is expected to report...
Edesa Biotech Inc. (EDSA) is expected to report $-0.71 for Q4 2023
2023-12-12 12:30:31 ET Gainers: C4 Therapeutics ( CCCC ) +85% . Aditxt ( ADTX ) +71% . Icosavax ( ICVX ) +48% . IN8bio ( INAB ) +31% . Petros Pharmaceuticals ( PTPI ) +31% . Clean Earth Acquisitions Corp ( CLIN ) +26% ...
2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-r...
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...